This article needs additional citations for verification. (June 2011) |
Clinical data | |
---|---|
Trade names | Cardiolite |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | NA |
Protein binding | 1% |
Metabolism | Nil |
Elimination half-life | Variable |
Excretion | Fecal (33%) and renal (27%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C36H66N6O6Tc |
Molar mass | 777 g·mol−1 |
3D model (JSmol) | |
| |
(verify) |
Technetium (99mTc) sestamibi (INN) (commonly sestamibi; USP: technetium Tc 99m sestamibi; trade name Cardiolite) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six (sesta=6) methoxyisobutylisonitrile (MIBI) ligands. The anion is not defined. The generic drug became available late September 2008. A scan of a patient using MIBI is commonly known as a "MIBI scan".
Sestamibi is taken up by tissues with large numbers of mitochondria and negative plasma membrane potentials.[1] Sestamibi is mainly used to image the myocardium (heart muscle). It is also used in the work-up of primary hyperparathyroidism to identify parathyroid adenomas, for radioguided surgery of the parathyroid and in the work-up of possible breast cancer.